Arbele

Arbele is a clinical-stage biopharmaceutical company focused on developing first-in-class immunotherapies for gastrointestinal (GI) cancers. The company utilizes its proprietary CDH17-targeting platform to address malignancies with high unmet needs, including gastric, pancreatic, and colorectal cancers. Its lead candidate, ARB202, is a bispecific antibody targeting CDH17 and CD3 that is currently in Phase 1 clinical trials. Beyond bispecifics, Arbele's pipeline includes CAR-NK cell therapies and diagnostic tools designed for early detection and precision treatment. With a global footprint spanning Hong Kong, the United States, Australia, and China, the company integrates multi-regional expertise to accelerate drug development. Arbele aims to transform the treatment landscape for GI cancers through its innovative focus on the Cadherin-17 biomarker.